1. Major primary prevention trials with statins
West Of Scotland Coronary Prevention Study (WOSCOPS) Air Force/Texas Coronary Atherosclerosis Prevention Study Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial—Lipid-Lowering Trial (ALLHAT—LLT) PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) Primary prevention of CV disease with pravastatin in Japan (MEGA) Primary prevention of CV disease with statin therapy: a meta-analysis of randomized controlled trials Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) 2. Major secondary prevention trials with statins
Scandinavian Simvastatin Survival Study (4S) PO Box 58871, London SE15 9BE, UK Telephone: +44 (0)7794 485294 Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) 3. Early statin treatment in ACS patients
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, pho- Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering tocopying, recording or otherwise, without the written permission of the copyright Effects of early treatment with statins on short-term clinical outcomes in ACS: The publisher and authors have made every effort to ensure the accuracy of the infor- a meta-analysis of randomized controlled trials mation in this book, but cannot accept responsibility for any errors or omissions. Any Atorvastatin for Reduction of MYocardial Damage during product mentioned in this publication should be used in accordance with the local prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.
4. CHD prevention trials with statins in patients with diabetes or 35
British Library Cataloguing in Publication Data the metabolic syndrome
A catalogue for this book is available from the British Library.
Collaborative AtoRvastatin Diabetes Study (CARDS) Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT—LLA) post-hoc diabetes subgroup analysis Manfred Kage, Peter Arnold Inc. / Science Photo Library Treating to New Targets (TNT) diabetes subgroup analysis TNT post-hoc metabolic syndrome subgroup analysis Evidence & Efficacy: Lipid-Modifying Therapy Atorvastatin Study for Prevention of coronary heart disease Endpoints 8. Meta-analyses for efficacy, safety and cost–benefit calculations 101
in Non-insulin-dependent diabetes mellitus (ASPEN) 5. CHD prevention in chronic kidney disease
Aspirin, statins or both drugs for the primary prevention of CHD events in men: a cost–utility analysis Die Deutsche Diabetes Dialyse (4D) Studie Analyses of cancer data from three ezetimibe trials 4S post-hoc mild chronic renal insufficiency subgroup analysis Primary prevention strategies for lipid lowering: a meta-analysis Statins and CV RR in patients with chronic kidney disease and 9. Primary prevention trials with CHD end points using drugs
6. Stroke prevention
that modify triglyceride-rich lipoproteins and/or HDL
World Health Organization (WHO) clofibrate study Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS) 7. Comparative hypolipidaemic efficacy, IVUS, IMT
and end-point trials
10. Secondary prevention trials with CHD end points using drugs 119
Comparative dose efficacy study of atorvastatin vs simvastatin, pravastatin, that modify triglyceride-rich lipoproteins and/or HDL
lovastatin and fluvastatin in patients with hypercholesterolaemia (CURVES) Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Veterans Affairs HDL Intervention Trial (VA-HIT) Statin Therapies for Elevated Lipid Levels compared Across dose ranges to HDL Atherosclerosis Treatment Study (HATS) Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Investigation of Lipid Level Management to Understand its Impact Reversal of atherosclerosis with aggressive lipid lowering therapy PRavastatin Or atorVastatin Evaluation and Infection Therapy—Thrombolysis Appendix: conversion calculator
In Myocardial Infarction 22 (PROVE-IT TIMI 22) Ezetimibe Add-on to Statin for Effectiveness (EASE) Incremental Decrease in End points through Aggressive Lipid lowering (IDEAL) 84 A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID) Meta-analysis of CV outcomes trials comparing intensive vs Measuring Effects on intima–media Thickness: an Evaluation Of Rosuvastatin Ezetimibe aNd simvastatin in Hypercholesterolemia enhANces atherosClerosis 94 Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol 6–HDL And LDL Treatment Strategies (ARBITER6–HALTS)

Source: http://www.cedillapublishing.com/data/EELMTEN2_TOC.pdf

Microsoft word - cv andrea allen 2011 08 30.doc

Andrea Allen Ph.D. EDUCATION B.A., 1971, Washington Square College, New York University Ph.D., 1976, Psychology (Social & Personality), Stanford University PSYCHOLOGY POSITIONS (New York State Licensed Psychologist, #012971) Mount Sinai Medical Center, Mount Sinai School of Medicine, New York, New York Assistant Clinical Professor of Psychology in Psychiatry, July 2009 to pr

Norvasc approved cpi

Medical Oxygen 99.5% Consumer Medicine Information What is in this leaflet? This leaflet answers some common questions about Medical Oxygen. It contains only some information, and does not take the place of talking to your doctor or appropriate healthcare professional. All medicines may assist you, but sometimes there are risks. Your doctor or healthcare professional has we

Copyright © 2010-2014 Online pdf catalog